Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HENGRUI PHARMA) has announced that it recently received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for the combination therapy of Camrelizumab for Injection with Apatinib Mesylate Tablets as a first-line treatment for patients with unresectable or metastatic hepatocellular carcinoma.
The regulatory feedback pertains primarily to observations from a Current Good Manufacturing Practice (CGMP) inspection of a production facility associated with Apatinib. This facility underwent an FDA CGMP surveillance inspection in April 2026. The company has conducted a detailed evaluation of the feedback provided by the regulatory agency and has initiated the formulation of corresponding corrective actions.
The relevant facility involved in this application successfully passed an inspection by the European Union in 2025. The CRL does not raise any issues concerning the clinical study data, safety, or efficacy of the product.
Hengrui Pharma will actively engage in close communication with the FDA and its partner, Elevar Therapeutics, to clarify the subsequent submission plan.
- Like
- Comment
- Favorite
Hengrui Pharma Receives FDA Complete Response Letter for Camrelizumab Injection Application
Stock News07-10 15:04
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Like
Report
Login to post
No comments yet